---
title: "NovoCure 2026 年第一季度财报预览"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/284613352.md"
description: "NovoCure (NVCR) 将于 4 月 30 日公布其第一季度财报，市场普遍预期每股收益（EPS）为-0.51 美元，同比下降 64.5%；预计收入为 1.6777 亿美元，同比增加 8.2%。在过去两年中，该公司有 63% 的时间超出每股收益和收入预期"
datetime: "2026-04-29T16:31:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284613352.md)
  - [en](https://longbridge.com/en/news/284613352.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284613352.md)
---

# NovoCure 2026 年第一季度财报预览

NovoCure (NVCR) is scheduled to announce Q1 earnings results on Thursday, April 30th, before market open. The consensus EPS Estimate is -$0.51 (-64.5% Y/Y) and the consensus Revenue Estimate is $167.77M (+8.2% Y/Y). Over the last 2 years, NVCR has beaten EPS estimates 63% of the time and has beaten revenue estimates 63% of the time. Over the last 3...

### 相关股票

- [NVCR.US](https://longbridge.com/zh-CN/quote/NVCR.US.md)
- [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/zh-CN/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md)

## 相关资讯与研究

- [CAR-T 迎接新时代](https://longbridge.com/zh-CN/news/286999381.md)
- [Aethlon Medical 密切关注刚果埃博拉疫情，重申大流行应对准备](https://longbridge.com/zh-CN/news/287246948.md)
- [创胜集团医药-B 合作伙伴 INHIBRX 报告 OZEKIBART 的 CRC 最新积极数据并宣布就治疗软骨肉瘤提交美国 BLA 申请](https://longbridge.com/zh-CN/news/287126678.md)
- [Tevogen Bio Q1 运营亏损收窄 48%，推进 AI 平台与细胞疗法管线](https://longbridge.com/zh-CN/news/287086570.md)
- [NovoCure｜8-K：2026 财年 Q1 营收 1.74 亿美元超过预期](https://longbridge.com/zh-CN/news/284753306.md)